Abstract Titles
Skip to Late-Breaking Abstracts »
All accepted abstracts will be available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Onsite Posters
Onsite posters will be presented in the Poster Hall at the Walter E. Washington Convention Center in Washington, D.C. All odd numbered posters will be presented on Friday, Nov. 12, 2021. Even numbered posters will be presented Saturday, Nov. 13, 2021.
ePosters
ePosters will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.
| # | Type | Title | Authors | Category | Keywords |
|---|---|---|---|---|---|
| 802 | Poster Presentation | An electronic health record-based approach to identify and characterize patients with immune checkpoint inhibitor-associated arthritis | Steven Tran, BS; Luke Rasmussen, MS; Jennifer Pacheco, MS; Carlos Galvez, MD; Kyle Tegtmeyer, MD; Yuan Luo, PhD; Jeffrey A. Sosman, MD; Abel Kho, MD; Theresa Walunas, PhD, MS | Immunotherapy Toxicities | Checkpoint blockade;Immune toxicity |
| 803 | Poster Presentation | Immune-related adverse events correlate with improved outcomes in patients with advanced non-small cell lung cancer treated with combinations of immune-checkpoint inhibitors and chemotherapy | Lindsey Shantzer, MD; Sean C. Dougherty, MD; Wendy Novicoff, PhD; John W. Melson, MD; Daniel R. Reed, MD; Alia C. Lynch, PharmD; Ryan D. Gentzler, MD, MS; Richard D. Hall, MD, MS | Immunotherapy Toxicities | Chemotherapy;Immune toxicity;Solid tumors |
| 804 | Poster Presentation | Real-world incidence and impact of pneumonitis in lung cancer patients treated with immune checkpoint inhibitors | Bruce C. Tiu, BS; Leyre Zubiri; James Iheke; Vartan Pahalyants, MD, MBA; Nicholas Theodosakis, MD; Pearl O. Ugwu-Dike; Jayhyun Seo; Kimberly Tang; Ryan J. Sullivan, MD; Meghan J. Mooradian, MD; Yevgeniy R. Semenov, MD; Kerry L. Reynolds, MD | Immunotherapy Toxicities | Checkpoint blockade;Clinical study;Epidemiology;Immune toxicity;Solid tumors;T cell;Targeted therapy |
| 805 | Oral Presentation | Clonal, activated CD8+ T cells recognizing cardiac alpha-myosin drive immune checkpoint inhibitor associated myocarditis in mice | Margaret L. Axelrod, BS; Wouter C. Meijers, MD,PhD; Elie Tannous, MD; Xiaopeng Sun, BS; Juan Qin, PhD; Ayaka Sugiura, BS; Elizabeth Wescott, BS; Elles M. Screever, BS; Spencer C. Wei, PhD; Susan Opalenik, BS, PhD; Yueli Zhang; Douglas B. Johnson, M.D.; James P. Allison, PhD; Javid Moslehi; Justin M. Balko, PhD, PharmD | Immunotherapy Toxicities | Autoimmunity;Checkpoint blockade;Immune tolerance;Immune toxicity;Inflammation;Neoantigens;T cell;Tumor antigens |
| 806 | Oral Presentation | PD-1 blockade affects inflammation and metabolic flexibility to potentially mediate cardiac immune-related adverse events | Steven M. Bronson, DVM; Elizabeth R. Stirling, MS; Brian Westwood, MS; Pierre L. Triozzi; David R. Soto-Pantoja, PhD | Immunotherapy Toxicities | Checkpoint blockade;Immune toxicity;Inflammation;Metabolism |
| 807 | Poster Presentation | Immunotherapy Related Adverse Events: A Single Center Experience | Wei Yang, MD; Sophia Lee, MD; Julie Rowe, MD; Jing Zhang; Mohammad Rahbar | Immunotherapy Toxicities | Chemotherapy;Immune toxicity |
| 808 | Poster Presentation | Tertiary lymphoid structure gene signature detected in immune checkpoint inhibitor-associated renal immune related adverse event | Jamie S. Lin, MD; Amanda Tchakarov; Noha Abdel-Wahab; Houssein Safa, MD; Salah-Eddine Bentebibel; Maen Abdelrahim, MD, PhD; Cassian Yee, MD; Adi Diab, MD; Ala Abudayyeh, MD | Immunotherapy Toxicities | Checkpoint blockade;Gene expression;Immune toxicity |
| 810 | Poster Presentation | Impact of immune-related adverse event development on overall survival in hospitalized lung cancer patients | Eric Olson, MD; Greg Russell; Jeffrey Lantz, DO; Andy Dothard, MD; Vanya Aggarwal, MD; Thomas W. Lycan, Jr., DO | Immunotherapy Toxicities | Checkpoint blockade;Immune monitoring;Immune toxicity;Solid tumors |
| 811 | Poster Presentation | Allelic variation in Human Leukocyte Antigen class II genes is associated with pneumonitis risk in cancer patients treated with immune checkpoint inhibitors | Ashis Saha, PhD; Christine N. Spencer, PhD; Zia Khan, PhD; Jonathan Carroll, PhD; Claudia Yanez Arellano; Julie Hunkapiller, PhD; Nicholas L. Bayless; Leonardo Nissola, MD; Roslyn Wallace, MBBS; Ira Mellman; Rajat Mohindra, MD; Samantha Bucktrout, PhD; Shahneen Sandhu, MBBS FRACP; G. Scott Chandler, MD; Christian Hammer, PhD | Immunotherapy Toxicities | Antigen presenting cells;Checkpoint blockade;Genetic polymorphism;Immune toxicity;Solid tumors;Systems biology;T cell |
| 812 | Poster Presentation | Erythema nodosum-like toxicity in an immunotherapy treated patient is accompanied by oligoclonal memory activated CD4 T cells | Xiaopeng Sun, BS; Margaret L. Axelrod, BS; Yu Wang, PhD; Sanchez Violeta; Paula I. Gonzalez-Ericsson, MD; Douglas B. Johnson, M.D.; Justin M. Balko, PhD, PharmD | Immunotherapy Toxicities | Checkpoint blockade;Immune toxicity;T cell |
| 813 | Poster Presentation | CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect | Mingyue Liu, PhD; Xu Wang; Peng Zhang; Juanjuan Su; Xuexiang Du; Yan Zhang; Yang Liu, PhD; Pan Zheng, MD, PhD | Immunotherapy Toxicities | Immune toxicity |
| 814 | Oral Presentation | Cutaneous Immune-related Adverse Events are Protective of Mortality in Patients Treated with anti-PD1 and anti-PDL1 therapy in a multi-institutional cohort study | Yevgeniy R. Semenov, MD; Kimberly Tang; Jayhyun Seo; Kerry L. Reynolds, MD; Bruce Tiu; Thomas Le; Vartan Pahalyants; Neel Raval; Pearl O. Ugwu-Dike; Leyre Zubiri; Vivek Naranbhai; Alexander Gusev; Nicole LeBoeuf; Maryam Asgari; Shawn Kwatra | Immunotherapy Toxicities | Biomarkers;Checkpoint blockade;Immune toxicity |
| 815 | Poster Presentation | Single-center retrospective cohort of all patients suspected to have immunotherapy-mediated diarrhea and colitis | Vanya Aggarwal, MD; Ella M. LePage, M.D.; Andrew Faucheux, M.D.; Hiral S. Patel, M.D.; Gregory B. Russell, M.S.; Eric Olson, MD; Jared J. Rejeski, M.D.; Thomas W. Lycan, Jr., DO | Immunotherapy Toxicities | Autoimmunity;Checkpoint blockade;Clinical study;Immune monitoring;Immune tolerance;Immune toxicity;Inflammation |
| 816 | Poster Presentation | Selective Immune Suppression using Interleukin-6 blockade in Immune Related Adverse Events | Faisal Fa'ak, MD; Faisal Fa'ak; Chrystia M. Zobniw; Maryam Buni; Linda Lu; Adewunmi Falohun; VanAnh Trinh; Muhammad Osama Awiwi; Khaled M Elsayes; Kaysia Ludford; Maya Dimitrova; Sabina Sandigursky; Amy Cunningham-Bussel; Jeffrey A. Sparks; Osama Abu-Shawer; Uma Thanarajasingam; Ashley M. Zeman; Rafee Talukder; Namrata Singh; Sarah H. Chung; Petros Grivas; May Daher; Ala Abudayyeh; Daniel Johnson; Maria Suarez-Almazor; Osama E. Rahma; Jeffrey S. Weber; Jean Tayar; Adi Diab; Noha Abdel-Wahab | Immunotherapy Toxicities | Checkpoint blockade;Cytokine;Immune suppression;Immune toxicity |
| 817 | Poster Presentation | Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study | Pankti Reid, MD, MPH; David F. Liew; Rajshi Akruwala; Anne Bass, MD; Karmela K. Chan, MD | Immunotherapy Toxicities | Checkpoint blockade;Immune monitoring;Immune toxicity |
Presented By:
